Last update 20 Dec 2025

HJ-004-02

Overview

Basic Info

Drug Type
Proteolysis-targeting chimeras (PROTAC)
Synonyms
HJ-004-02
Target
EGFR
Action
modulators
Mechanism
EGFR modulators(Epidermal growth factor receptor erbB1 modulators)
Therapeutic Areas
NeoplasmsRespiratory Diseases
Active Indication
EGFR positive Non-squamous non-small cell lung cancerEGFR-mutated non-small Cell Lung Cancer
Inactive Indication-
Originator Organization
Jing Medicine Technology Shanghai Ltd.Jing Medicine Technology Shanghai Ltd.
Active Organization
Jing Medicine Technology Shanghai Ltd.Jing Medicine Technology Shanghai Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with HJ-004-02
ChiCTR2500112428
/ Not yet recruitingPhase 1IIT
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Anti-tumor Efficacy of HJ-004-02 Tablets in Patients with Advanced Non-squamous Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Mutations
CTR20254077
/ Not yet recruitingPhase 1
一项评价 HJ-004-02 片在表皮生长因子受体（EGFR）突变的晚期非鳞状非小细胞肺癌患者中的安全性、耐受性、药代动力学特征和初步抗肿瘤疗效的 I 期临床试验
[Translation] A Phase I clinical trial evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary antitumor efficacy of HJ-004-02 tablets in patients with advanced non-squamous non-small cell lung cancer and epidermal growth factor receptor (EGFR) mutations
100 Clinical Results associated with HJ-004-02
Login to view more data
100 Translational Medicine associated with HJ-004-02
Login to view more data
100 Patents (Medical) associated with HJ-004-02
Login to view more data
100 Deals associated with HJ-004-02
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
EGFR positive Non-squamous non-small cell lung cancerPhase 1
China
Jing Medicine Technology Shanghai Ltd.Jing Medicine Technology Shanghai Ltd.
11 Oct 2025
EGFR-mutated non-small Cell Lung CancerIND Approval
United States
Jing Medicine Technology Shanghai Ltd.Jing Medicine Technology Shanghai Ltd.
28 Oct 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free